Shire resubmits NDA for lifitegrast to FDA

Resubmission includes positive data from OPUS-3, a Phase III efficacy and safety trial.

Addressing the FDA request for an additional study, Shire included in its NDA resubmission package data from OPUS-3, a Phase III efficacy and safety trial with a primary endpoint of patient-reported symptom improvement. The resubmission package also included information requested by the FDA regarding product quality.

“The NDA for lifitegrast now includes data from five randomized controlled clinical trials, with more than 2,500 patients, making it the largest data set for an investigational stage compound in dry eye disease to date,” said Philip J. Vickers, Head of R&D, Shire. “Because we believe that, if approved, lifitegrast has the potential to help the millions of US adults living with symptoms of dry eye disease, we worked diligently to submit our response to the CRL as quickly as possible. This is an important milestone for Shire and underscores our commitment to providing innovative new treatment options in areas of unmet medical need.”

The new drug application for lifitegrast now includes data from one Phase II study, three Phase III efficacy and safety studies (OPUS-1, OPUS-2 and OPUS-3), and one long-term (one-year) Phase III safety study (SONATA).

The FDA has 30 days after resubmission of an NDA to acknowledge receipt and determine if the submission is a complete response. Upon acceptance, the FDA will provide Shire with a PDUFA date anticipated to be within 6 months of the date of submission.